Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Schizophrenia

DMT for Schizophrenia

14 papers and 0 clinical trials exploring dmt as a treatment for schizophrenia.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationApproximately 24 million people worldwide are affected by schizophrenia.

Schizophrenia

Schizophrenia is a complex psychiatric disorder characterised by disruptions in thought processes and perception. Recent research into psychedelics has opened new avenues for understanding its neurobiology and exploring potential therapeutic mechanisms, particularly in addressing treatment-resistant symptoms.

Full Schizophrenia profile

Academic Research

14 papers
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
December 1, 2024
Journal
JAMA Psychiatry
Authors
Hinkle, J. T., Graziosi, M., Nayak, S., Yaden, D. B.
Open Accessmeta

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

This systematic review (2024) and meta-analysis (s=131) examines the incidence of psychedelic-induced psychosis, focusing on individuals with schizophrenia. It finds an incidence of 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs, with 3.8% of UCT participants with schizophrenia developing long-lasting psychotic symptoms. It also reports that 13.1% of those with psychedelic-induced psychosis later developed schizophrenia.

Published
November 27, 2024
Journal
Molecular Psychiatry
Authors
Sabé, M., Sulstarova, A., Glangetas, A., De Pieri, M., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L., Seragnoli, F., Thorens, G., Zullino, D., Preller, K., Böge, K., Leucht, S., Correll, C. U., Solmi, M., Kaiser, S., Kirschner, M.
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
March 10, 2023
Journal
Psyarxiv
Authors
Turkia, M.
Open Accessmeta

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

This review evaluates evidence that serotonergic psychedelics (5‑HT2A agonists such as LSD, psilocybin and DMT) may ameliorate social deficits and co‑occurring anxiety and depression in autism spectrum disorder. It highlights neurobiological constraints (synaptic, serotonergic, prefrontal and thalamocortical dysfunction), mixed and sometimes adverse outcomes in historical paediatric trials, and concludes that rigorous contemporary studies are needed to determine whether benefits outweigh risks and whether 5‑HT2A is a viable therapeutic target.

Published
January 27, 2022
Journal
Frontiers in Pharmacology
Authors
Markopoulos, A., Inserra, A., De Gregorio, D., Gobbi, G.
Paywallmeta

The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies

This meta-analysis (2021) of brain imaging studies finds that under the influence of psychedelics (tryptamines), the most changes in connectivity are indeed the ones where there are the most 5-HT1a/2a receptors. Other regions are also highlighted, and these regions most influenced are responsible for mental imagery, theory of mind, and affective regulation.

Published
September 7, 2021
Journal
Frontiers in Pharmacology
Authors
Castelhano, J. M., Lima, G. M., Teixeira, M., Soares, C., Pais, M., Castelo-Branco, M.
Paywallmeta

Research abuses against people of colour and other vulnerable groups in early psychedelic research

This review of early psychedelic studies (the 50s-70s, s=48) finds that most (77%) would not pass ethical review today. The errors made in early research were extensive dosing, lack of consent, inadequate setting, and lack of scientific hypotheses. The authors make restorative justice and cultural competency suggestions.

Published
July 12, 2021
Journal
Journal of Medical Ethics
Authors
Strauss, D., de la Salle, S., Sloshower, J. A., Williams, M. T.

Clinical Trials

0 trials

No clinical trials have been tagged with both DMT and Schizophrenia yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all DMT papers Search all Schizophrenia trials Full DMT profile Full Schizophrenia profile